Life Sciences Central DesignerApplication · Oracle

CVE-2026-21970

MEDIUM · 6.5 CVSS v3.1 Published 2026-01-20
Mitigation only
No fix yet — a mitigation exists. There is no fixed release. A documented workaround reduces exposure in the meantime.
See remediation →
71/100
Remediation priority · Elevated
Remotely reachable Zero-click

Official description Straight from the sourceThe vendor's or NVD's own wording, published unedited. Authoritative, but often terse — it says what broke, rarely what to do.

NVD · unedited
Vulnerability in the Oracle Life Sciences Central Designer product of Oracle Health Sciences Applications (component: Platform). The supported version that is affected is 7.0.1.0. Easily exploitable vulnerability allows low privileged attacker with network access via HTTP to compromise Oracle Life Sciences Central Designer. Successful attacks of this vulnerability can result in unauthorized access to critical data or complete access to all Oracle Life Sciences Central Designer accessible data. CVSS 3.1 Base Score 6.5 (Confidentiality impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N).

Technical summary Written by usOur analysis, written from the advisory, the CVSS vector and the affected-version data. It adds context the advisory leaves out, and never invents facts that are not in the source.

dbcve analysis · high confidence

Web-based authorization vulnerability in Oracle Life Sciences Central Designer platform component allows low-privileged authenticated attackers via HTTP to access sensitive data beyond their authorized scope. The CVSS vector indicates a network-exploitable, low-complexity attack with high confidentiality impact but no integrity or availability impact.

MitigationApply Oracle's security patch for version 7.0.1.0 when available. Implement network segmentation, restrict HTTP/HTTPS access to trusted IPs, and deploy WAF rules as interim controls.

Verify against the referenced sources before acting — the references below are authoritative for this CVE, this summary is not.

Affected products & versions What the vendor confirmedThe version ranges the vendor confirmed as vulnerable. If your version sits inside a range here, treat yourself as exposed until you have upgraded.

NVD · CPE data
Life Sciences Central DesignerApplication
Affected:= 7.0.1.0

CVSS breakdown How the score is builtThe industry scoring standard. It rates how the flaw is reached, what it takes to exploit, and what an attacker gains — the score is derived from those, not the other way round.

From the vector
Attack vector
Network
Complexity
Low
Privileges
Low
User interaction
None
Scope
Unchanged
Confidentiality
High
Integrity
None
Availability
None

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

Am I affected? How to checkSteps we derive from the advisory and the affected-version data, so you can decide whether this CVE reaches your setup. They are a guide, not a scan — your own configuration is the authority.

dbcve checks

Work through these to decide whether this CVE applies to you.

  1. Identify installed Oracle Life Sciences Central Designer version
    Locate the Central Designer installation directory and check the version manifest, about page, or version file within the product. Alternatively, query the Oracle database for product version tables if accessible through Central Designer administrative interfaces.
    Affected if The installed version is exactly 7.0.1.0
  2. Verify web interface is enabled and accessible
    Confirm that the Central Designer web component (HTTP/HTTPS listener) is running and reachable on the network. Check if the application responds to requests on typical web ports.
    Affected if The web interface is exposed and responds to HTTP/HTTPS requests
  3. Confirm authentication is configured
    Verify that user authentication is enabled in Central Designer and that low-privileged user accounts exist within the system.
    Affected if Low-privileged authenticated users can log in to the platform
  4. Check authorization boundaries
    Review user role assignments and data access permissions within Central Designer to understand the defined authorization scope for different user roles.
    Affected if Users with limited roles can potentially access data outside their assigned scope through the web interface

A user is affected if they are running exactly version 7.0.1.0 of Oracle Life Sciences Central Designer with its web interface accessible and low-privileged accounts configured, allowing unauthorized data access beyond role permissions.

Generated from the published advisory. Verify against your own configuration.

Check your environment

Paste your version and any relevant configuration and it will be compared against the affected criteria above. Do not include secrets or credentials.

AI-assisted, checked against the advisory. Informational, not a guarantee.

Remediation Closing itWhat it takes to close this. Where a vendor fix exists we point at it; where none exists we say so plainly, and can build one. Effort estimates are scoped from the advisory, not from your codebase.

From vendor data
Mitigation available No clean upgrade yet — mitigate in the meantime
Mitigation

Apply Oracle's security patch for version 7.0.1.0 when available. Implement network segmentation, restrict HTTP/HTTPS access to trusted IPs, and deploy WAF rules as interim controls.

Fix this in Life Sciences Central Designer Scoped from the published advisory
  • Consultation2.0 h
  • Implementation4.0 h
  • Testing6.0 h
  • Review / QA3.0 h
15.0 hours of engineering $2,560
Get help mitigating

An estimate, not a bill — we confirm scope with you before any work starts. Need it this week? Rush from $4,096.

Scan for this in your stack

Free · runs locally
dbcve dependency scanner

Check whether your project pulls in CVE-2026-21970 — or any other known-vulnerable package — straight from your lock files. Free and open source; it runs locally and uploads nothing.

References Go to the primary sourcePrimary sources — vendor advisories, patches and trackers. Where our summary and a reference disagree, the reference wins.

Primary sources

Practitioner notes

Contributed

Peer-ranked notes from engineers who’ve handled CVE-2026-21970 in production — separate from our analysis above.

No notes yet

Be the first to add a field note for this CVE — a mitigation you’ve verified, a version caveat, or a link to a working fix. Sign in above to contribute.

What this is

A place for practitioners to share what actually worked: a mitigation you’ve tested, a configuration change, a version- or environment-specific caveat, or a link to a verified patch. The most useful notes rise to the top as peers upvote them, so the signal stays high.

What belongs here
  • Verified mitigations, workarounds, and config changes
  • Version or environment caveats, and links to real fixes
  • No weaponised exploit code, or anything meant to cause harm
  • No spam, self-promotion, credentials, or personal data